Skye Bioscience Doses First Patient in Nimacimab Study Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data will determine impact.

Skye Bioscience Doses First Patient in Nimacimab Study: Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data… 👈 Read full analysis #SkyeBioscience #Nimacimab #ClinicalTrials #Biotechnology #Pharmaceuticals

Skye Bioscience Highlights Nimacimab’s Promise as a Safer, Next-Generation Obesity Treatment Skye Bioscience (NASDAQ: SKYE) is putting its lead drug candidate, nimacimab, into the spotlight following new scientific presentations and a broader media push

#SKYE is spotlighting the promise of nimacimab, its innovative monoclonal antibody therapy, as a safer next-generation option for obesity and metabolic disorders.
#skyebioscience
prismmarketview.com/skye-bioscie...

PRISM Mid-Day Movers:
#COMPASSPathways ( #CMPS) dives 45%
#wearehims & Hers ( #HIMS) drops 30%
Other PRISM Mid-Day Movers:
• CorMedix Inc. ( #CRMD) up 17.85%
• #skyebioscience , Inc. ( #SKYE) up 28.66%
• Houston American Energy Corp. ( #HUSA) up 43.78%
prismmarketview.com/prism-mid-da...